Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
+0.25%
1,104.10
+2.73
+0.25%
—1,101.371,103.631,105.311,091.41——
SIXC
Communications
SIXC
Communications
SIXC
-1.50%
604.16
-9.19
-1.50%
—613.35613.35613.35601.49——
SIXE
Energy
SIXE
Energy
SIXE
-0.09%
1,197.81
-1.02
-0.09%
—1,198.831,199.681,199.751,182.41——
SIXI
Industrials
SIXI
Industrials
SIXI
-0.88%
1,740.41
-15.54
-0.88%
—1,755.951,754.061,756.031,734.69——
SIXM
Financials
SIXM
Financials
SIXM
-0.64%
634.44
-4.07
-0.64%
—638.51637.41637.41633.05——
SIXR
Staples
SIXR
Staples
SIXR
-0.31%
840.90
-2.62
-0.31%
—843.52843.35846.40837.93——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
-0.38%
215.13
-0.82
-0.38%
—215.95215.95216.84215.06——
SIXT
Technology
SIXT
Technology
SIXT
+2.86%
3,228.71
+89.80
+2.86%
—3,138.913,189.303,230.853,174.76——
SIXU
Utilities
SIXU
Utilities
SIXU
+0.16%
935.87
+1.50
+0.16%
—934.37934.72938.26927.50——
SIXV
Health care
SIXV
Health care
SIXV
-1.37%
1,457.12
-20.31
-1.37%
—1,477.431,474.121,474.121,451.80——
SIXY
Discretionary
SIXY
Discretionary
SIXY
+0.83%
2,399.84
+19.65
+0.83%
—2,380.192,389.342,403.042,380.47——
ABVX:NASDAQ
Abivax SA
$114.56
+1.38%
(+1.56) 1D
$114.00
-0.49% (-0.56)
After hours
Closed: Apr 24, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ABVX...
Open
$113.00
High
$115.57
Low
$110.60
Mkt. cap
7.59B
Avg. vol.
1.05M
Volume
889.62K
52-wk high
$148.83
52-wk low
$5.59
Shares outstanding
79.29M
No. of employees
69
News stories
From sources across the web
Profile
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated. The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
About Abivax SA
CEOHartmut J. Ehrlich
Employees69
FoundedDec 4, 2013
Headquarters-
SectorBiotechnology
Websiteabivax.com
Previous reportsAll values in EUR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in EUR
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Revenue
970.00K
1.05M
639.00K
1.91M
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
39.30M
38.64M
55.42M
44.40M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
8.89M
8.94M
27.34M
27.69M
Operating expense
48.17M
47.54M
81.35M
73.56M
Total operating expenses
48.17M
47.54M
81.35M
73.56M
Operating income
-47.20M
-46.50M
-80.71M
-71.65M
Other non operating income
431.00K
2.66M
-74.20M
-4.96M
EBT including unusual items
-52.37M
-48.41M
-153.36M
-76.11M
EBT excluding unusual items
-51.32M
-48.41M
-153.36M
-80.84M
Income tax expense
-
-
-
5.85M
Effective tax rate
-
-
-
-7.68%
Other operating expenses
-24.00K
-46.00K
-1.40M
1.47M
Net income
-52.37M
-48.41M
-153.36M
-81.96M
Net profit margin
-5,398.97%
-4,624.07%
-23,999.69%
-4,282.13%
Earnings per share
-
-
-
-
Interest and investment income
859.00K
190.00K
3.36M
1.19M
Interest expense
-4.54M
-3.52M
-4.21M
-15.27M
Net interest expenses
-3.68M
-3.33M
-852.00K
-14.08M
Depreciation and amortization charges
-
-
-
-
EBITDA
-47.12M
-46.47M
-80.63M
-70.76M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer